Abstracts tagged "Inflammation"

Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 0149 • ACR Convergence 2023
Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study
Colleen Burke¹, Michael Brown², Kenneth Taylor², Stephanie Danyluk², Kelley Seebeck² and Adam Goode³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…
Abstract Number: 0553 • ACR Convergence 2023
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Anastasiia Phothisane¹, Shahensha Shaik¹, Qiong Wu¹, Olivia Posey¹, Sean Davies², Jaya Krishnan¹, David Patrick³, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…
Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Annie Law¹, Chee Jian Pua², Dianyang Guo³, Chin Teck Ng⁴, Julian Thumboo¹, Andrea Hsiu Ling Low⁵ and Xiubo Fan¹, ¹Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²National Heart Centre, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Ashmia Saif¹, Hafsa Nomani², Frank Hwang², Jie Yang² and Qingping Yao², ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
Abstract Number: 1713 • ACR Convergence 2023
Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
Elisa Dalix¹, Mathieu Maalouf¹, Robin Caire², Guillaume Courbon¹, Virginie Dumas³, Sylvie Peyroche¹, Marie-Thérèse Linossier¹, Mireille Thomas¹, Charles-Antoine Arthaud¹, Arnaud Vanden-Bossche¹ and Hubert Marotte⁴, ¹Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, ³Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, ⁴CHU Saint-Etienne, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
Abstract Number: 1777 • ACR Convergence 2023
The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function
Aenea Brugman¹, Órla Tynan², Dumitru Anton³, Carl Orr⁴, Viviana Marzaioli⁵, Douglas Veale⁶ and Ursula Fearon⁷, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin; EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ³Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁶St.Vincent's University Hosp, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Ireland
Background/Purpose: While common pathogenic mechanisms exist between PsA and RA, distinct vascular morphology has been observed, with PsA displaying a tortuous, dilated, irregular shaped morphology…
Abstract Number: 2206 • ACR Convergence 2023
Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
Eric Toussirot¹, Caroline Laheurte², Eléonore Gravelin², Charline Vauchy³, Marc Puyraveau³ and Philippe Saas⁴, ¹University Hospital of Besancon, Besançon, France, ²INSERM UMR1098, plateforme de biomonitoring, EFS Bourgogne-Franche-Comté, Besançon, France, ³INSERM CIC-1431, Besançon, France, ⁴INSERM UMR1098, EFS Bourgogne-Franche-Comté, Besançon, France
Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…
Abstract Number: 2569 • ACR Convergence 2023
Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
Sara Bindoli¹, Arianna De Matteis², STEPHANE MITROVIC³, Bruno Fautrel⁴, Loreto Carmona⁵, Fabrizio De Benedetti⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ⁴Sorbonne Université APHP, Paris, France, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…
Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Hanan Ibrahim¹ and Alireza Meysami², ¹Henry Ford Health System (HFHS), Detroit, MI, ²Henry Ford Health, Detroit, MI
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…
Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Tobias Schmidt¹, Christina Brock², Jesper Fleischer³, Søren Jacobsen¹ and Amanda Hempel Zinglersen¹, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…
Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Françis Bonnefoy¹, Susanne Behlke² and Sylvain Perruche¹, ¹Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, ²MedINNPharma, Besançon, France
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1717 • ACR Convergence 2023
Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis
Nathalie Burg¹, Miles Tran², Kevin Wei³, Carl Blobel¹ and Jane Salmon¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (EC), but the contribution of ECs to inflammatory arthritis…
Abstract Number: 1778 • ACR Convergence 2023
Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Chiara Rizzo¹, Lidia La Barbera¹, Marianna Lo Pizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Dieli¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: The inflammatory process characterizing Psoriatic Arthritis (PsA) is mainly driven by interleukin (IL)-23/IL-17 axis and IL-9 overexpression, in presence of T helper (Th)17 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].